Chris L Waller
Overview
Explore the profile of Chris L Waller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agrafiotis D, Holloway M, Johnson S, Reynolds C, Stouch T, Tropsha A, et al.
J Comput Aided Mol Des
. 2018 Jul;
32(7):723-729.
PMID: 30039202
No abstract available.
2.
Brown F, Kopti F, Chang C, Johnson S, Glick M, Waller C
AAPS J
. 2017 Aug;
19(5):1255-1263.
PMID: 28770387
Merck & Co., Inc., Kenilworth, NJ, USA, is undergoing a transformation in the way that it prosecutes R&D programs. Through the adoption of a "model-driven" culture, enhanced R&D productivity is...
3.
Verras A, Waller C, Gedeck P, Green D, Kogej T, Raichurkar A, et al.
J Chem Inf Model
. 2017 Mar;
57(3):445-453.
PMID: 28257198
The development of new antimalarial therapies is essential, and lowering the barrier of entry for the screening and discovery of new lead compound classes can spur drug development at organizations...
4.
Kutchukian P, So S, Fischer C, Waller C
Methods Mol Biol
. 2015 Feb;
1289:43-53.
PMID: 25709032
Fragment based screening (FBS) has emerged as a mainstream lead discovery strategy in academia, biotechnology start-ups, and large pharma. As a prerequisite of FBS, a structurally diverse library of fragments...
5.
Ekins S, Waller C, Bradley M, Clark A, Williams A
Drug Discov Today
. 2012 Oct;
18(5-6):265-71.
PMID: 23098820
Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of...
6.
Gupta R, Gifford E, Liston T, Waller C, Hohman M, Bunin B, et al.
Drug Metab Dispos
. 2010 Aug;
38(11):2083-90.
PMID: 20693417
Ligand-based computational models could be more readily shared between researchers and organizations if they were generated with open source molecular descriptors [e.g., chemistry development kit (CDK)] and modeling algorithms, because...
7.
Ekins S, Gupta R, Gifford E, Bunin B, Waller C
Pharm Res
. 2010 Aug;
27(10):2035-9.
PMID: 20683645
Cheminformatics is at a turning point, the pharmaceutical industry benefits from using the various methods developed over the last twenty years, but in our opinion we need to see greater...
8.
Waller C, Shah A, Nolte M
Drug Discov Today
. 2007 Aug;
12(15-16):634-9.
PMID: 17706544
Much progress has been made over the past several years to provide technologies for the integration of drug discovery software applications and the underlying data bits. Integration at the application...
9.
Jalaie M, Arimoto R, Gifford E, Schefzick S, Waller C
Methods Mol Biol
. 2004 May;
275:449-520.
PMID: 15141126
Preventing drug-drug interactions and reducing drug-related mortalities dictate cleaner and costlier medicines. The cost to bring a new drug to market has increased dramatically over the last 10 years, with...
10.
Waller C
J Chem Inf Comput Sci
. 2004 Mar;
44(2):758-65.
PMID: 15032558
The three-dimensional quantitative structure-activity relationship (QSAR) technique of comparative molecular field analysis (CoMFA) has demonstrated the ability to provide accurate predictions for diverse chemical compounds when trained with molecules of...